Skip to main content

Pande Vijay Satyanand's Form 4 filing

BioAge Labs, Inc. (BIOA) · filed Sep 27, 2024

Accession no.
0001415889-24-024047
Filed
Sep 27, 2024
Trade date
Sep 27, 2024
Filing delay
Same day
Rule 10b5-1 plan
Not checked

This filing lists 5 non-derivative transactions and 4 derivative transactions. Open-market purchases total $16.2M. It was filed on the trade date.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Pande Vijay SatyanandCIK 0001840663Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 27, 2024Common StockCConversionAcquired+855,972––855,972Indirect
Sep 27, 2024Common StockCConversionAcquired+413,100––1,269,072Indirect
Sep 27, 2024Common StockCConversionAcquired+189,609––189,609Indirect
Sep 27, 2024Common StockCConversionAcquired+655,294––655,294Indirect
Sep 27, 2024Common StockPPurchaseAcquired+900,000$18.00+$16,200,000900,000Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Sep 27, 2024Common StockCConversionDisposed−855,972––0Indirect
Sep 27, 2024Common StockCConversionDisposed−413,100––0Indirect
Sep 27, 2024Common StockCConversionDisposed−189,609––0Indirect
Sep 27, 2024Common StockCConversionDisposed−655,294––0Indirect

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)